Wednesday, July 8, 2026

biotech · Type 1 Diabetes · Coronavirus · SABS

SAB Biotherapeutics

SAB Biotherapeutics patent portfolio — 1 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Gaithersburg, USA HQ
2016 Founded
39 Employees
Public company Type
SABS · NYSE Ticker
Company details
Status
Public
HQ
Gaithersburg, USA
Founded
2016
Employees
39
Programs
8
Drugs
10
Patents
1
Intelligence · Patents

SAB Biotherapeutics patents

1 pharmaceutical patents indexed for SAB Biotherapeutics. 0 expire within 24 months.

SAB Biotherapeutics has 1 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 11975066

    Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does SAB Biotherapeutics have?

1 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do SAB Biotherapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.